253 related articles for article (PubMed ID: 22353999)
1. Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.
Radivoyevitch T; Hlatky L; Landaw J; Sachs RK
Blood; 2012 May; 119(19):4363-71. PubMed ID: 22353999
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in the incidence of chronic myeloid leukemia.
Radivoyevitch T; Jankovic GM; Tiu RV; Saunthararajah Y; Jackson RC; Hlatky LR; Gale RP; Sachs RK
Radiat Environ Biophys; 2014 Mar; 53(1):55-63. PubMed ID: 24337217
[TBL] [Abstract][Full Text] [Related]
3. Biologically based risk estimation for radiation-induced CML. Inferences from BCR and ABL geometric distributions.
Radivoyevitch T; Kozubek S; Sachs RK
Radiat Environ Biophys; 2001 Mar; 40(1):1-9. PubMed ID: 11357705
[TBL] [Abstract][Full Text] [Related]
4. Biologically-based risk estimation for radiation-induced chronic myeloid leukemia.
Radivoyevitch T; Hoel DG
Radiat Environ Biophys; 2000 Sep; 39(3):153-9. PubMed ID: 11095145
[TBL] [Abstract][Full Text] [Related]
5. Modeling the low-LET dose-response of BCR-ABL formation: predicting stem cell numbers from A-bomb data.
Radivoyevitch T; Hoel DG
Math Biosci; 1999; 162(1-2):85-101. PubMed ID: 10616282
[TBL] [Abstract][Full Text] [Related]
6. [Clinical epidemiology].
Ohyashiki K
Nihon Rinsho; 2001 Dec; 59(12):2416-20. PubMed ID: 11766349
[TBL] [Abstract][Full Text] [Related]
7. The risk of chronic myeloid leukemia: can the dose-response curve be U-shaped?
Radivoyevitch T; Kozubek S; Sachs RK
Radiat Res; 2002 Jan; 157(1):106-9. PubMed ID: 11754648
[TBL] [Abstract][Full Text] [Related]
8. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia.
Costello R; Sainty D; Lafage-Pochitaloff M; Gabert J
Leuk Lymphoma; 1997 Apr; 25(3-4):225-32. PubMed ID: 9168433
[TBL] [Abstract][Full Text] [Related]
10. Chronic myelogenous leukemia: biology and therapy.
Gale RP; Grosveld G; Canaani E; Goldman JM
Leukemia; 1993 Apr; 7(4):653-8. PubMed ID: 8464245
[TBL] [Abstract][Full Text] [Related]
11. Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.
Lu X; Song X; Ye Y; Liu X; Zhou Y; Zhang L; Wang J; Ying B; Wang L
Mol Biol Rep; 2011 Jun; 38(5):3101-5. PubMed ID: 20127176
[TBL] [Abstract][Full Text] [Related]
12. Accurate prediction of the age incidence of chronic myeloid leukemia with an improved two-mutation mathematical model.
Lecca P; Sorio C
Integr Biol (Camb); 2016 Dec; 8(12):1261-1275. PubMed ID: 27801472
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2014 May; 89(5):547-56. PubMed ID: 24729196
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia in 2007.
Sessions J
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S4-9. PubMed ID: 18056931
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
16. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
Sillaber C; Mayerhofer M; Agis H; Sagaster V; Mannhalter C; Sperr WR; Geissler K; Valent P
Wien Klin Wochenschr; 2003 Aug; 115(13-14):485-504. PubMed ID: 13677268
[TBL] [Abstract][Full Text] [Related]
18. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
19. Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries.
Radivoyevitch T
Radiat Environ Biophys; 2021 Mar; 60(1):41-47. PubMed ID: 33125593
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal.
Aguiar RC
Leuk Lymphoma; 1998 Mar; 29(1-2):17-26. PubMed ID: 9638972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
